Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics

Keyphrases

• Cardiovascular Prevention 100%
• Cholesterol 100%
• Baseline Characteristics 100%
• Blood Pressure Lowering 75%
• Placebo 50%
• Nonfatal Myocardial Infarction 50%
• Cardiovascular Mortality 50%
• Intermediate Risk 50%
• Blood Pressure Level 50%
• Major Adverse Cardiovascular Events 50%
• Statin Drugs 50%
• Nonfatal Stroke 50%
• Rosuvastatin 25%
• Cardiovascular Risk 25%
• Cardiovascular Disease 25%
• Cardiac Arrest 25%
• Blood Pressure 25%
• Antihypertensive Drugs 25%
• Primary Prevention 25%
• Heart Failure 25%
• 2-factorial Design 25%
• High-risk Population 25%
• North America 25%
• High-risk Individuals 25%
• Vascular Events 25%
• South America 25%
• Asia 25%
• South Europe 25%
• Hydrochlorothiazide 25%
• Arterial Revascularization 25%
• Candesartan 25%
• South Australia 25%
• Cholesterol-lowering 25%
• Low-risk Population 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Cardiovascular Disease 100%
• Heart Infarction 100%
• Placebo 100%
• Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor 100%
• Rosuvastatin 50%
• Cardiovascular Risk 50%
• Heart Arrest 50%
• Antihypertensive Agent 50%
• Heart Failure 50%
• Hydrochlorothiazide 50%
• Candesartan 50%

Medicine and Dentistry

• Blood Pressure 100%
• Cardiovascular Disease Prevention 100%
• Cardiovascular System 66%
• Apoplexy 33%
• Myocardial Infarction 33%
• Placebo 33%
• Statin 33%
• Cardiovascular Disease 16%
• Cardiovascular Risk 16%
• Heart Arrest 16%
• Primary Prevention 16%
• Antihypertensive Agent 16%
• Heart Failure 16%
• Revascularization 16%
• Low Drug Dose 16%
• Contraindication 16%
• Low Risk Population 16%
• Candesartan 16%
• Rosuvastatin 16%
• Intermediate Risk Population 16%
• Hydrochlorothiazide 16%